Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.72 |
| ▸ | CDK4 | P11802 | 9/20 | 0.72 |
| ▸ | CDK9 | P50750 | 6/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.53 |
| ▸ | CDK7 | P50613 | 4/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 4/20 | 0.45 |
| ▸ | AURKA | O14965 | 3/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CCNH | P51946 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087336 | 0.89 | CDK2 (0.56) | CDK2CDK4CDK9CCNT1CDK7 | |
| SCHEMBL2086429 | 0.88 | CDK2 (0.69) | CDK2CDK4CDK9CCNT1CDK7 | |
| SCHEMBL2087794 | 0.87 | CDK2 (0.55) | CDK2CDK4CDK9CCNT1CDK7 | |
| SCHEMBL29369233 | 0.84 | CDK2 (1.00) | CDK2CDK4CDK9CCNT1CDK7 | |
| SCHEMBL4798545 | 0.84 | CDK2 (1.00) | CDK2CDK4CDK9CCNT1CDK7 | |
| SCHEMBL2088261 | 0.83 | MKNK2 (0.54) | CDK2CDK4CDK9CCNT1CDK7 | |
| SCHEMBL2086596 | 0.81 | CDK2 (0.70) | CDK2CDK4CDK9CCNT1CDK7 | |
| SCHEMBL2084979 | 0.80 | CDK2 (0.65) | CDK2CDK4CDK9CCNT1CDK7 | |
| SCHEMBL4613610 | 0.79 | CDK2 (0.58) | CDK2CDK4CDK9CCNT1CDK7 | |
| SCHEMBL2087781 | 0.77 | CDK2 (0.62) | CDK2CDK4CDK9CCNT1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678171-B1 | 2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2016-09-14 | — | — | EP | claimed |
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | claimed |
| EP-1951307-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | Cyclacel Limited (GB) | 2008-08-06 | — | — | EP | claimed |
| WO-2007054725-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | CYCLACEL LIMITED (GB) | 2007-05-18 | — | — | WO | claimed |
| JP-2007509117-A | — | — | 2007-04-12 | — | — | JP | claimed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| EP-1678171-A1 | PYRIMIDIN-4-YL-3,4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2006-07-12 | — | — | EP | claimed |
| WO-2005042525-A1 | PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | claimed |
| EP-1678171-B1 | 2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| EP-1951307-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | Cyclacel Limited (GB) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007054725-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | CYCLACEL LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1678171-A1 | PYRIMIDIN-4-YL-3,4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042525-A1 | PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | MSRB3, DHFR, CBR3 | CDK2 459/4885CDK4 703/4885CDK9 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.